Aventis to exit rabies vaccine JV with Novartis in India
This article was originally published in Scrip
Executive Summary
Aventis Pharma is exiting its rabies vaccine joint venture with Novartis in India.
You may also be interested in...
Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSK’s Chiron Behring
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.